ENvue Medical Inc (FEED) Risk Analysis

The Staff of Nasdaq have had discussions with the Company with respect to the Company's Agreement and Plan of Merger (the "Merger Agreement") with EnVue Medical Holdings, Corp ("EnVue"), dated February 14, 2025. Pursuant to the terms of the Merger Agreement, the Company issued 1,734,995 shares of Common Stock and 57,720 shares of Series X Non-Voting Convertible Preferred Stock with provisions for the preferred shares to convert into 57,720,000 shares of Common Stock subject to shareholder approval. On April 4, 2025, Staff determined that the Company's transition with EnVue, a non-Nasdaq entity, constitutes a business combination that will result in a "Change of Control" upon shareholder approval to convert the Series X Non-Voting Convertible Preferred Stock. Pursuant to Listing Rule 5110(a) (the "Rule"), the post-transaction entity will be required to satisfy all of Nasdaq's initial listing criteria and to complete Nasdaq's initial listing process, including the payment of all applicable fees, prior to the shareholder vote to approve the conversion of the Preferred Shares discussed below, or other material changes triggering a change of control. The Company previously updated the Staff with respect to the Company's operations following the closing of the Merger Agreement to clarify that the Company's legacy NanoVibronix, Inc. business continued to operate in the same manner as prior to closing. Recently, the Staff has inquired again with respect to the Company's operations, namely those of the legacy NanoVibronix, Inc. business, particularly in light of the Company's financial results and operations, as well as changes in management and the members of the Board of Directors since the closing of the transactions contemplated by the Merger Agreement. As part of this inquiry, the Staff noted that it believed the Company's transaction with EnVue constituted a "Change of Control" requiring the Company to meet the initial listing requirements of Nasdaq, with respect to which the Company has never satisfied since the closing of that transaction. The Staff, however, has provided the Company with the opportunity to rebut this determination. If the Staff conclusively determines that the transactions contemplated by the Merger Agreement constituted a "Change of Control" that otherwise violates the Rule, Nasdaq could immediately delist the Company's Common Stock. If such a delisting determination were to occur, the Company's Common Stock would be immediately suspended from trading on Nasdaq.

Our stockholders may from time to time seek to acquire a controlling stake in the Company, engage in proxy solicitations, advance stockholder proposals or otherwise attempt to effect changes. Campaigns by stockholders to effect changes at publicly traded companies are sometimes led by investors seeking to increase short-term stockholder value through actions such as financial restructuring, increased debt, special dividends, stock repurchases or sales of assets or the entire company. Responding to proxy contests and other actions by activist stockholders can be costly and time-consuming. These actions could adversely affect our operations, financial condition, and the value of our common stock.

Almost all of our assets are located outside the United States, although we do maintain a permanent place of business within the United States. In addition, some of our officers and directors are nationals and/or residents of countries other than the United States, and all or a substantial portion of such persons' assets are located outside the United States. As a result, it may be difficult for investors to enforce within the United States any judgments obtained against us or any of our non-U.S. directors or officers, including judgments predicated upon the civil liability provisions of the securities laws of the United States or any state thereof. Additionally, it may be difficult to assert U.S. securities law claims in actions originally instituted outside of the United States. Israeli courts may refuse to hear a U.S. securities law claim because Israeli courts may not be the most appropriate forums in which to bring such a claim. Even if an Israeli court agrees to hear a claim, it may determine that the Israeli law, and not U.S. law, is applicable to the claim. Further, if U.S. law is found to be applicable, certain content of applicable U.S. law must be proved as a fact, which can be a time-consuming and costly process, and certain matters of procedure would still be governed by the Israeli law. Consequently, you may be effectively prevented from pursuing remedies under U.S. federal and state securities laws against us or any of our non-U.S. directors or officers.

Pursuant to the terms of the Series G Certificate of Designations, on the fifth (5th) anniversary of the issuance date (the "Mandatory Conversion Date"), all then outstanding shares of Series G Preferred Stock and, to the extent that we elect to pay dividends in duly authorized, validly issued, fully paid and non-assessable shares of common stock, all accrued but unpaid dividends thereon through and including the Mandatory Conversion Date shall be automatically converted into shares of common stock, subject to beneficial ownership limitations applicable to each holder. Such mandatory conversion could result in substantial dilution to our existing shareholders, including a significant increase in the number of shares of our common stock outstanding, which may reduce the ownership percentage and voting power of existing stockholders. In addition, the issuance of a large number of shares of common stock upon conversion, or the expectation that such issuance may occur, could adversely affect the market price of our common stock and increase volatility in our trading price. Furthermore, to the extent that at the time of such mandatory conversion we do not have a sufficient number of authorized but unissued and unreserved shares of common stock to effect the conversion in full, we may be required to seek stockholder approval to increase our authorized share capital, which may not be obtained in a timely manner or at all. Any delay in obtaining such approval could result in a failure to timely satisfy our obligations under the Series G Preferred Stock, potentially constituting a breach of the applicable Certificate of Designations and giving rise to additional rights or remedies for holders, including potential penalties or adjustments that could be adverse to us. Even if sufficient authorized shares are available, effecting such mandatory conversion will reduce the number of shares of common stock available for future issuances, including for financings, acquisitions, equity incentive plans, or other corporate purposes. This reduction could limit our flexibility to raise additional capital or pursue strategic transactions on favorable terms, or at all, which could adversely affect our business, financial condition, and results of operations.

Additional issuances and sales of preferred stock, or the perception that such issuances and sales could occur, may cause prevailing market prices for our common stock to decline and may adversely affect our ability to raise additional capital in the financial markets at times and prices favorable to us.

We are a "smaller reporting company" and, thus, have certain decreased disclosure obligations in our SEC filings, including, among other things, simplified executive compensation disclosures and only being required to provide two years of audited financial statements in annual reports. Decreased disclosures in our SEC filings due to our status as a "smaller reporting company" may make it harder for investors to analyze our results of operations and financial prospects and may make our common stock a less attractive investment. If some investors find our common stock less attractive, there may be a less active trading market for our common stock and our stock price may be more volatile.

Although our shares of common stock are listed on Nasdaq under the symbol "FEED," trading volume in our common stock has been limited and an active trading market for our shares of common stock may never develop or be maintained. The absence of an active trading market increases price volatility and reduces the liquidity of our common stock. As long as this condition continues, the sale of a significant number of shares of common stock at any particular time could be difficult to achieve at the market prices prevailing immediately before such shares are offered.

Certain provisions of our amended and restated certificate of incorporation and bylaws could discourage, delay or prevent a Merger, acquisition or other change of control that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. Furthermore, these provisions could prevent or frustrate attempts by our stockholders to replace or remove members of our Board of Directors (the "Board" or "Board of Directors"). These provisions also could limit the price that investors might be willing to pay in the future for our securities, thereby depressing the market price of our securities. Stockholders who wish to participate in these transactions may not have the opportunity to do so. These provisions, among other things: - allow the authorized number of directors to be changed only by resolution of our Board; - authorize our Board to issue, without stockholder approval, preferred stock, the rights of which will be determined at the discretion of the Board and that, if issued, could operate as a "poison pill" to dilute the stock ownership of a potential hostile acquirer to prevent an acquisition that our Board does not approve; - establish advance notice requirements for stockholder nominations to our Board or for stockholder proposals that can be acted on at stockholder meetings; and - limit who may call a stockholder meeting. In addition, we are governed by the provisions of Section 203 of the Delaware General Corporation Law that may, unless certain criteria are met, prohibit large stockholders, in particular those owning 15% or more of the voting rights on our common stock, from merging or combining with us for a prescribed period of time.

The trading market for our securities will depend in part on the research and reports that securities or industry analysts publish about us or our business. Currently there is only one research coverage by a securities and industry analyst. If one or more of the analysts who covers us downgrades our securities, the price of our securities would likely decline. If one or more of these analysts ceases to cover us or fails to publish regular reports on us, interest in the purchase of our securities could decrease, which could cause the price of our securities and their trading volume to decline.

We expect that the price of our securities will fluctuate significantly. Market prices for securities of early-stage medical device companies have historically been particularly volatile. In addition to the factors discussed in this "Risk Factors" section and elsewhere in this Annual Report, these factors include: - progress, or lack of progress, in developing and commercializing our products; - favorable or unfavorable decisions about our products or intellectual property from government regulators, insurance companies or other third-party payers; - our ability to recruit and retain qualified regulatory and research and development personnel; - changes in investors' and securities analysts' perception of the business risks and conditions of our business; - changes in our relationship with key collaborators; - changes in the market valuation or earnings of our competitors or companies viewed as similar to us; - changes in key personnel; - depth of the trading market in our common stock; - changes in our capital structure, such as future issuances of securities or the incurrence of additional debt; - the granting or exercise of employee stock options or other equity awards; - realization of any of the risks described under this section entitled "Risk Factors"; and - general market and economic conditions. In recent years, the stock markets, in general, have experienced extreme price and volume fluctuations especially in the biotechnology sector. Broad market and industry factors may materially harm the market price of shares of our common stock. In the past, following periods of volatility in the market price of a company's securities, securities class action litigation has often been instituted against that company. If we were involved in any similar litigation, we could incur substantial costs and our management's attention and resources could be diverted. In the recent past, the U.S. and global markets have been experiencing volatility and disruption following the escalation of geopolitical tensions and the start of the military conflict between Russia and Ukraine, and Israel and certain hostile entities. A continuation or worsening of the levels of market disruption and volatility could have an adverse effect on our ability to access capital, on our business, results of operations and financial condition, and on the market price of our common stock.

Sales of a significant number of shares of our common stock in the public market could harm the market price of our common stock and make it more difficult for us to raise funds through future offerings of common stock. Our stockholders and the holders of our outstanding warrants and options, upon exercise of these options or warrants, may sell substantial amounts of our common stock in the public market. The availability of these shares of our common stock for resale in the public market has the potential to cause the supply of our common stock to exceed investor demand, thereby decreasing the price of our common stock. In addition, the fact that our stockholders and holders of our warrants and options can sell substantial amounts of our common stock in the public market, whether or not sales have occurred or are occurring, could make it more difficult for us to raise additional financing through the sale of equity or equity-related securities in the future at a time and price that we deem reasonable or appropriate.

Each share of the Series H Convertible Preferred Stock (the "Series H Preferred Stock") is entitled to receive cumulative dividends at the rate per share of 9% per annum (as a percentage of the stated value per share), payable on each conversion date (with respect to only the shares of Series H Preferred Stock being converted), in duly authorized, validly issued, fully paid and non-assessable shares of common stock at the conversion price then on effect in accordance with the terms of the Certificate of Designations. As such, we may rely on having available shares of common stock to pay such dividends, which will result in dilution to our shareholders. If we do not have such available shares, we may not be able to satisfy our obligations as related to these dividends pursuant to the terms of the Certificate of Designations.

Certain events, for example, a Dilutive Issuance (as defined in each of the Series G Certificate of Designations and the Series H Certificate of Designations) may reduce the conversion price of the Series G Preferred Stock and/or Series H Preferred Stock, as applicable, which in turn may lead to further dilution to the holders of our common stock. In addition, the perceived risk of dilution may cause our shareholders to be more inclined to sell their common stock, which may in turn depress the price of common shares regardless of our business performance. We may also find it more difficult to raise additional equity capital while any of the shares of the Series G Preferred Stock or the Series H Preferred Stock remain outstanding.

The principal purpose of the 2025 Reverse Stock Split was to increase the trading price of our common stock to meet the minimum stock price standards of Nasdaq. However, the effect of a reverse stock split on the market price of our common stock cannot be predicted with any certainty, and we cannot assure you that a reverse stock split will accomplish this objective for any meaningful period of time, or at all. While we expect that the reduction in the number of outstanding shares of common stock will proportionally increase the market price of our common stock, we cannot assure you that a reverse stock split will increase the market price of our common stock by a multiple of any reverse stock split ratio, or result in any permanent or sustained increase in the market price of our common stock sufficient to regain compliance with the conditions required by the Panel. The market price of our common stock may be affected by other factors which may be unrelated to the number of shares outstanding, including our business and financial performance, general market conditions, and prospects for future success.

The 2025 Reverse Stock Split reduced the total number of outstanding shares of common stock, which may lead to reduced trading and a smaller number of market makers for our common stock, particularly if the price per share of our common stock does not increase as a result of a reverse stock split.